メディア掲載記事

Dr. Murphy of ICON, provider of clinical services to Pfizer/BioNTech’s COVID vaccine program, discusses what it takes to conduct a vaccine trial of this scale.

Morgan Hill, Principal, Global Medical Communications, offers insights on the evolution of healthcare messaging and how ICON is staying at the forefront of communicating healthcare messages and data.

In this article, Angela Brown and Nicole Cowan provide an overview of today’s regulatory setting and discuss how manufacturers can develop strategies to ensure a successful transition to comply with the IVDR by the 2022 deadline.

​An article discussing how the pandemic spread caused disruption but also a rapid deployment of solutions to ensure continuity in clinical trials and preserve and build resilience into ongoing research programmes.

Michael Pellegrino, SVP of Global Medical Communications, outlines research on patient involvement in the journal review process.

ICON’s David Morse, VP, Global Regulatory Affairs Consulting Services talks to Business Insider on regulatory pathways for development of new vaccines and vaccine boosters to address emerging COVID-19 variants.

Michael Pellegrino, SVP of Global Medical Communications weighs in on how industry has increasingly recognised the benefits of different communications for specific purposes and audiences.

ICON’s Dr. Andrew Garrett, Executive Vice President Scientific Operations, talks to Politico on clinical trials to test COVID-19 transmission in the community.

An article discussing the challenges caused by the pandemic and how the environment has had to rely on technology, thus changing the traditional landscape of clinical research.

An article explaining how ICON was involved from the very first steps of the trial supporting Pfizer‘s and BioNTech’s implementation of a strategic plan and framework for the monitoring of the trial.